Business Context and Reporting Period
This Form 8-K Current Report was filed by 10x Genomics, Inc. on November 12, 2025. The report discloses a significant change in executive leadership regarding the Chief Legal Officer position, effective January 1, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure: Eric S. Whitaker announced his retirement as Chief Legal Officer after more than eight years of service, effective January 1, 2026.
- Transition Role: Mr. Whitaker will remain an employee with reduced compensation in the new role of Strategic Counsel to assist with ongoing legal matters.
- Appointment: Dr. Randy Wu, currently Vice President of Intellectual Property and Litigation, has been appointed to succeed Mr. Whitaker as General Counsel and Secretary, effective January 1, 2026.
Management Commentary and Outlook
CEO Serge Saxonov praised Mr. Whitaker's leadership, judgment, and integrity, noting his critical role from the company's IPO through complex legal challenges. Regarding the appointment, Mr. Saxonov highlighted Dr. Wu's nearly decade-long tenure, deep institutional knowledge, and practical approach, expressing confidence in his ability to build upon the existing foundation.
Investor Verification Checklist
- Confirm the exact effective date of the leadership transition (January 1, 2026).
- Verify Dr. Randy Wu's current title and tenure prior to this appointment.
- Review the terms of Mr. Whitaker's transition to Strategic Counsel, specifically regarding compensation adjustments.
- Check for any pending litigation or legal matters that may require immediate attention during the transition period.